We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has BioLife Solutions (BLFS) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioLife Solutions (BLFS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BioLife Solutions is a member of our Medical group, which includes 761 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. BLFS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for BLFS's full-year earnings has moved 177.78% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that BLFS has returned about 252% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.81% on a year-to-date basis. As we can see, BioLife Solutions is performing better than its sector in the calendar year.
To break things down more, BLFS belongs to the Medical - Products industry, a group that includes 70 individual companies and currently sits at #94 in the Zacks Industry Rank. On average, this group has gained an average of 12.35% so far this year, meaning that BLFS is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on BLFS as it attempts to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has BioLife Solutions (BLFS) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioLife Solutions (BLFS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BioLife Solutions is a member of our Medical group, which includes 761 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. BLFS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for BLFS's full-year earnings has moved 177.78% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that BLFS has returned about 252% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.81% on a year-to-date basis. As we can see, BioLife Solutions is performing better than its sector in the calendar year.
To break things down more, BLFS belongs to the Medical - Products industry, a group that includes 70 individual companies and currently sits at #94 in the Zacks Industry Rank. On average, this group has gained an average of 12.35% so far this year, meaning that BLFS is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on BLFS as it attempts to continue its solid performance.